New study tests safer eczema treatment for pakistani patients
NCT ID NCT07437534
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares two steroid-free ointments—crisaborole and tacrolimus—for treating mild-to-moderate eczema in 148 Pakistani patients aged 2 and older. Researchers will measure skin improvement and side effects over 8 weeks to see which works better and is safer. The goal is to provide local evidence for better eczema care.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
crisaborole 2% ointment and tacrolimus 0.1% ointment
What this could lead to
If successful, this could help doctors choose safer, more effective eczema treatments for Pakistani patients, especially children.
What could go wrong
This is a small, early-phase study in one country, so results may not apply elsewhere. Both drugs have known side effects like burning or cancer risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hayatabad Medical Complex
Peshawar, KPK, Pakistan
Contact Phone: •••-•••-•••• Email: •••••@•••••